Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Quality of life and outcomes in African Americans with CKD.

Porter A, Fischer MJ, Wang X, Brooks D, Bruce M, Charleston J, Cleveland WH, Dowie D, Faulkner M, Gassman J, Hiremath L, Kendrick C, Kusek JW, Norris KC, Thornley-Brown D, Greene T, Lash JP; AASK Study Group.

J Am Soc Nephrol. 2014 Aug;25(8):1849-55. doi: 10.1681/ASN.2013080835. Epub 2014 Apr 3.

2.

Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD.

Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Contreras G, Faulkner ML, Hiremath L, Jamerson KA, Lea JP, Lipkowitz MS, Pogue VA, Rostand SG, Smogorzewski MJ, Wright JT, Greene T, Gassman J, Wang X, Phillips RA; African American Study of Kidney Disease and Hypertension (AASK) Study Group.

Clin J Am Soc Nephrol. 2012 Nov;7(11):1770-6. doi: 10.2215/CJN.11301111. Epub 2012 Aug 30.

3.

Net endogenous acid production is associated with a faster decline in GFR in African Americans.

Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA; African American Study of Kidney Disease and Hypertension Study Group.

Kidney Int. 2012 Jul;82(1):106-12. doi: 10.1038/ki.2012.82. Epub 2012 Apr 4.

4.

Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.

Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC; AASK Study Group.

Am J Kidney Dis. 2011 Dec;58(6):886-93. doi: 10.1053/j.ajkd.2011.07.018. Epub 2011 Sep 22.

5.

Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.

Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, Charleston J, Dowie D, Thornley-Brown D, Cooper LA, Bruce MA, Kusek JW, Norris KC, Lash JP; AASK Study Group.

Kidney Int. 2011 Sep;80(6):670-8. doi: 10.1038/ki.2011.153. Epub 2011 Jun 1.

6.

Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease.

Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, Charleston J, Dowie D, Thornley-Brown D, Cooper LA, Bruce MA, Kusek JW, Norris KC, Lash JP; AASK study group.

Kidney Int. 2010 Jun;77(11):1010-9. doi: 10.1038/ki.2010.38. Epub 2010 Mar 3.

7.

CRP polymorphisms and progression of chronic kidney disease in African Americans.

Hung AM, Crawford DC, Griffin MR, Brown-Gentry K, Lipkowitz MS, Siew ED, Cavanaugh K, Lewis JB, Ikizler TA; AASK Study Group.

Clin J Am Soc Nephrol. 2010 Jan;5(1):24-33. doi: 10.2215/CJN.01900309. Epub 2009 Dec 3.

8.

Association of a CYP4A11 variant and blood pressure in black men.

Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ; AASK Study Group.

J Am Soc Nephrol. 2008 Aug;19(8):1606-12. doi: 10.1681/ASN.2008010063. Epub 2008 Apr 2.

9.

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.

Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J; AASK Study Group.

Am J Kidney Dis. 2006 Nov;48(5):739-51.

PMID:
17059993
10.

A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension.

Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr; AASK Study Group.

J Am Soc Nephrol. 2004 Dec;15(12):3175-83.

11.

Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.

Lea JP, Brown DT, Lipkowitz M, Middleton J, Norris K; AASK Study Group.

Am J Cardiovasc Drugs. 2003;3(3):193-200. Review.

PMID:
14727931
12.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group.

JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726.

PMID:
12435255
13.

Successful blood pressure control in the African American Study of Kidney Disease and Hypertension.

Wright JT Jr, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, Randall O, Rogers N, Smith MC, Massry S; African American Study of Kidney Disease and Hypertension Study Group.

Arch Intern Med. 2002 Jul 22;162(14):1636-43.

PMID:
12123409
14.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group.

JAMA. 2001 Jun 6;285(21):2719-28.

PMID:
11386927
Items per page

Supplemental Content

Loading ...
Write to the Help Desk